7Baggers
 SCYNEXIS announces favourable Phase I data for SCY-247 trial  Clinical Trials Arena Wed, 01 Oct 2025 10:51:21 GMT
 SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247  Investing.com Nigeria Wed, 01 Oct 2025 06:46:24 GMT
 SCYNEXIS reports positive Phase 1 results for antifungal drug SCY-247  Investing.com India Tue, 30 Sep 2025 12:36:24 GMT
 Can SCYNEXIS (NASDAQ:SCYX) Afford To Invest In Growth?  simplywall.st Tue, 09 Sep 2025 07:00:00 GMT
 investors' lawsuit against scynexis dismissed, case closed  TradingView Fri, 05 Sep 2025 13:59:53 GMT
 Scynexis Released from Investor’s Lawsuit Over Drug Recall Risk  Bloomberg Law News Tue, 02 Sep 2025 07:00:00 GMT
 published on: 2025-09-01 06:33:03  Newser Mon, 01 Sep 2025 11:33:03 GMT
 scynexis reports q2 eps (14c), consensus (19c)  MSN Sun, 31 Aug 2025 00:31:41 GMT

SCYNEXIS, Inc
(NASDAQ:SCYX) 

SCYX stock logo

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, i...

Full Time Employees: 27
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic

Share this website to your friends